HK1219731A1 - 喹硫平的氨基酸綴合物、其製備和使用方法 - Google Patents
喹硫平的氨基酸綴合物、其製備和使用方法Info
- Publication number
- HK1219731A1 HK1219731A1 HK16107736.6A HK16107736A HK1219731A1 HK 1219731 A1 HK1219731 A1 HK 1219731A1 HK 16107736 A HK16107736 A HK 16107736A HK 1219731 A1 HK1219731 A1 HK 1219731A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- quetiapine
- making
- amino acid
- same
- acid conjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D267/18—[b, e]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D281/16—[b, f]-condensed
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29157609P | 2009-12-31 | 2009-12-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1219731A1 true HK1219731A1 (zh) | 2017-04-13 |
Family
ID=44226775
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15110951.9A HK1210046A1 (zh) | 2009-12-31 | 2015-11-06 | 喹硫平的氨基酸綴合物、其製備和使用方法 |
HK16107736.6A HK1219731A1 (zh) | 2009-12-31 | 2016-07-04 | 喹硫平的氨基酸綴合物、其製備和使用方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15110951.9A HK1210046A1 (zh) | 2009-12-31 | 2015-11-06 | 喹硫平的氨基酸綴合物、其製備和使用方法 |
Country Status (10)
Country | Link |
---|---|
US (6) | US8715699B2 (zh) |
EP (2) | EP2987789A1 (zh) |
JP (2) | JP5544024B2 (zh) |
CN (3) | CN102781236B (zh) |
AU (1) | AU2010336981B2 (zh) |
CA (4) | CA2889457C (zh) |
ES (1) | ES2548031T3 (zh) |
HK (2) | HK1210046A1 (zh) |
IL (1) | IL220664A (zh) |
WO (1) | WO2011082076A1 (zh) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102781236B (zh) * | 2009-12-31 | 2015-01-07 | 凯姆制药公司 | 喹硫平的氨基酸缀合物、其制备和使用方法 |
EP2544536B1 (en) | 2010-03-11 | 2018-12-12 | Kempharm, Inc. | Fatty acid conjugates of quetiapine, process for making and using the same |
JP2015527365A (ja) | 2012-08-21 | 2015-09-17 | オルソ−クリニカル ダイアグノスティクス,インコーポレイティド | パリペリドンに対する抗体及びその使用 |
TR201816378T4 (tr) | 2012-08-21 | 2018-11-21 | Janssen Pharmaceutica Nv | Olanzapin haptenleri. |
JP6216926B2 (ja) | 2012-08-21 | 2017-10-25 | ヤンセン ファーマシューティカ エヌ.ベー. | オランザピンに対する抗体及びその使用 |
ES2669565T3 (es) | 2012-08-21 | 2018-05-28 | Janssen Pharmaceutica Nv | Haptenos de risperidona y paliperidona |
CA2882615C (en) | 2012-08-21 | 2019-07-09 | Ortho-Clinical Diagnostics, Inc. | Antibodies to quetiapine and use thereof |
AU2013305970B2 (en) | 2012-08-21 | 2017-08-17 | Saladax Biomedical Inc. | Antibodies to aripiprazole haptens and use thereof |
AU2013305879B2 (en) | 2012-08-21 | 2017-10-12 | Saladax Biomedical Inc. | Antibodies to aripiprazole and use thereof |
EP2888257B1 (en) * | 2012-08-21 | 2017-08-02 | Janssen Pharmaceutica NV | Haptens of quetiapine for use in immunoassays |
CA2882563C (en) | 2012-08-21 | 2022-11-29 | Eric Hryhorenko | Antibodies to risperidone haptens and use thereof |
PL2888234T3 (pl) | 2012-08-21 | 2018-07-31 | Janssen Pharmaceutica Nv | Hapteny arypiprazolu i ich zastosowanie w testach immunologicznych |
CN104837838A (zh) | 2012-08-21 | 2015-08-12 | 詹森药业有限公司 | 帕潘立酮半抗原 |
CA2882597C (en) | 2012-08-21 | 2020-04-14 | Ortho-Clinical Diagnostics, Inc. | Antibodies to quetiapine haptens and use thereof |
WO2014031603A1 (en) | 2012-08-21 | 2014-02-27 | Ortho-Clinical Diagnostics, Inc | Antibodies to paliperidone haptens and use thereof |
EP3933406A3 (en) | 2012-08-21 | 2022-04-20 | Janssen Pharmaceutica NV | Antibodies to risperidone and use thereof |
AU2013305895B2 (en) | 2012-08-21 | 2017-10-19 | Saladax Biomedical Inc. | Antibodies to olanzapine haptens and use thereof |
WO2015081891A1 (en) * | 2013-12-06 | 2015-06-11 | Baikang (Suzhou) Co., Ltd | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs |
US20170056352A1 (en) | 2015-08-25 | 2017-03-02 | Rgenix, Inc. | PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF |
JP6994461B2 (ja) | 2015-12-17 | 2022-02-04 | ヤンセン ファーマシューティカ エヌ.ベー. | クエチアピンに対する抗体及びその使用 |
US10444250B2 (en) | 2015-12-17 | 2019-10-15 | Janssen Pharmaceutica Nv | Antibodies to risperidone and use thereof |
WO2018160178A1 (en) | 2017-03-01 | 2018-09-07 | Rgenix, Inc. | Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof |
MX2020005924A (es) * | 2017-12-08 | 2021-05-27 | Chromocell Corp | Derivados de triptofano como endulzantes. |
WO2021119316A1 (en) | 2019-12-11 | 2021-06-17 | Rgenix, Inc. | Methods of treating cancer |
CN111808046B (zh) * | 2020-06-30 | 2022-11-11 | 杭州同舟生物技术有限公司 | 一种喹硫平人工半抗原、人工抗原及其制备方法和应用 |
CN115028986B (zh) * | 2022-06-27 | 2023-06-23 | 重庆泰山电缆有限公司 | 电缆护套材料及制备方法 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4064138A (en) | 1975-11-12 | 1977-12-20 | General Mills, Inc. | Amino acid derivatives |
GB8607684D0 (en) | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
DE69125750D1 (de) * | 1990-05-21 | 1997-05-28 | Abbott Lab | Fettsäure-Oberflächenaktives-Lungenprotein Konjate |
DE69320378T2 (de) * | 1992-01-21 | 1999-04-29 | Macrochem Corp | Iontophoretische verbesserte Verabreichung von Medikamenten |
GB9403857D0 (en) * | 1994-03-01 | 1994-04-20 | Scotia Holdings Plc | Fatty acid derivatives |
US6623752B1 (en) * | 1996-07-02 | 2003-09-23 | Hexal Ag | Patch for transdermal application for pergolid |
US5955459A (en) * | 1997-11-26 | 1999-09-21 | Neuromedica, Inc. | Fatty acid-antipsychotic compositions and uses thereof |
US6197764B1 (en) * | 1997-11-26 | 2001-03-06 | Protarga, Inc. | Clozapine compositions and uses thereof |
US7060708B2 (en) * | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
GB9922271D0 (en) * | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Formulation |
US20070225379A1 (en) * | 2001-08-03 | 2007-09-27 | Carrara Dario Norberto R | Transdermal delivery of systemically active central nervous system drugs |
JP2005508625A (ja) | 2001-08-31 | 2005-04-07 | ザ ロックフェラー ユニバーシティー | 抗精神病薬の分類方法 |
US7544681B2 (en) | 2001-09-27 | 2009-06-09 | Ramot At Tel Aviv University Ltd. | Conjugated psychotropic drugs and uses thereof |
CA2461663A1 (en) * | 2001-09-27 | 2003-04-03 | Ramot At Tel Aviv University Ltd. | Conjugated anti-psychotic drugs and uses thereof |
US7700561B2 (en) * | 2002-02-22 | 2010-04-20 | Shire Llc | Abuse-resistant amphetamine prodrugs |
IL163666A0 (en) | 2002-02-22 | 2005-12-18 | New River Pharmaceuticals Inc | Active agent delivery systems and methods for protecting and administering active agents |
US7393920B2 (en) * | 2003-06-23 | 2008-07-01 | Cem Corporation | Microwave-assisted peptide synthesis |
EP1644005B1 (en) * | 2003-07-02 | 2010-08-18 | AstraZeneca AB | Metabolite of quetiapine |
WO2005002587A1 (en) * | 2003-07-02 | 2005-01-13 | Astrazeneca Ab | Quetiapine metabolite with antipsychotic activity |
CN1925865B (zh) * | 2003-09-30 | 2011-09-14 | 希拉有限责任公司 | 防止用药过量或滥用的药物组合物 |
NZ546226A (en) | 2003-09-30 | 2009-03-31 | Shire Llc | Oxycodone conjugates for prevention of overdose or abuse |
CN101005829A (zh) * | 2003-10-21 | 2007-07-25 | 艾克塔维斯集团公司 | 喹硫平制剂 |
US20050171088A1 (en) | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
DE602006011127D1 (de) * | 2005-01-27 | 2010-01-28 | Ocean Nutrition Canada Ltd | Fettsäure-benzenediol-derivate sowie herstellungs- und verwendungsverfahren dafür |
CN101193650A (zh) * | 2005-04-08 | 2008-06-04 | 新河药品股份有限公司 | 抗滥用的苯丙胺前体药物 |
WO2007004236A2 (en) | 2005-07-04 | 2007-01-11 | Ramu Krishnan | Improved drug or pharmaceutical compounds and a preparation thereof |
JP2009526073A (ja) * | 2006-02-09 | 2009-07-16 | ユニバーシティ オブ バージニア パテント ファンデーション | 二環式スフィンゴシン−1−リン酸受容体アナログ |
EP2077860B1 (en) * | 2006-10-25 | 2014-04-09 | Ramot at Tel-Aviv University Ltd | Psychotropic agents having glutamate nmda activity |
JP2010514682A (ja) | 2006-12-20 | 2010-05-06 | アストラゼネカ・アクチエボラーグ | 化合物及びその使用 |
CN102781236B (zh) * | 2009-12-31 | 2015-01-07 | 凯姆制药公司 | 喹硫平的氨基酸缀合物、其制备和使用方法 |
EP2544536B1 (en) | 2010-03-11 | 2018-12-12 | Kempharm, Inc. | Fatty acid conjugates of quetiapine, process for making and using the same |
-
2010
- 2010-12-22 CN CN201080065046.1A patent/CN102781236B/zh not_active Expired - Fee Related
- 2010-12-22 AU AU2010336981A patent/AU2010336981B2/en not_active Ceased
- 2010-12-22 CA CA2889457A patent/CA2889457C/en not_active Expired - Fee Related
- 2010-12-22 JP JP2012547158A patent/JP5544024B2/ja not_active Expired - Fee Related
- 2010-12-22 CA CA2964809A patent/CA2964809C/en not_active Expired - Fee Related
- 2010-12-22 US US13/518,981 patent/US8715699B2/en active Active
- 2010-12-22 CN CN201410743376.1A patent/CN104586859B/zh not_active Expired - Fee Related
- 2010-12-22 CA CA2927380A patent/CA2927380C/en not_active Expired - Fee Related
- 2010-12-22 US US12/976,546 patent/US20110183963A1/en not_active Abandoned
- 2010-12-22 ES ES10841599.3T patent/ES2548031T3/es active Active
- 2010-12-22 EP EP15181057.9A patent/EP2987789A1/en not_active Withdrawn
- 2010-12-22 WO PCT/US2010/061853 patent/WO2011082076A1/en active Application Filing
- 2010-12-22 CA CA2785846A patent/CA2785846C/en not_active Expired - Fee Related
- 2010-12-22 CN CN201710931283.5A patent/CN107714703A/zh active Pending
- 2010-12-22 EP EP10841599.3A patent/EP2519101B1/en not_active Not-in-force
-
2012
- 2012-06-27 IL IL220664A patent/IL220664A/en not_active IP Right Cessation
-
2014
- 2014-03-17 US US14/216,342 patent/US9597403B2/en active Active
- 2014-05-02 JP JP2014095248A patent/JP5753610B2/ja not_active Expired - Fee Related
-
2015
- 2015-11-06 HK HK15110951.9A patent/HK1210046A1/zh not_active IP Right Cessation
-
2016
- 2016-07-04 HK HK16107736.6A patent/HK1219731A1/zh unknown
-
2017
- 2017-02-13 US US15/431,054 patent/US20170209586A1/en not_active Abandoned
- 2017-05-15 US US15/595,374 patent/US10010615B2/en active Active
- 2017-05-15 US US15/595,380 patent/US20170246308A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1219731A1 (zh) | 喹硫平的氨基酸綴合物、其製備和使用方法 | |
HRP20190057T1 (hr) | Konjugati kvetiapina s masnom kiselinom, postupak izrade i uporaba istih | |
IL237471A (en) | Annals of [[(s1) –2– isopropoxy – 1 – methyl – 2 – oxo-ethyl] amino] –phenoxy – phosphoryl | |
HRP20130456T1 (en) | Novel process for the preparation of amino acid derivatives | |
PL2462223T3 (pl) | Oksydaza fruktozyloaminokwasowa | |
EP2291419A4 (en) | POLYMACROMONOMER AND PROCESS FOR PRODUCING THE SAME | |
IL216305A0 (en) | Solid forms and process for preparing | |
EG26786A (en) | Fertilizers contain sulfur and process to manufacture | |
PL2151428T3 (pl) | Nowy sposób syntezy agomelatyny | |
PL2358662T3 (pl) | Sposób amonolizy kwasu 11-bromoundekanowego | |
PL2137206T3 (pl) | Sposób wytwarzania kwasu tauroursodeoksycholowego | |
EP2436678A4 (en) | TRIALLYLISOCYANURATE AND MANUFACTURING METHOD THEREFOR | |
EP2415869A4 (en) | MODIFIED OLIGO-NUCLEIC ACID MOLECULE, PROCESS FOR PREPARATION AND USES THEREOF | |
SI2151429T1 (sl) | Postopek za pripravo agomelatina | |
EG26332A (en) | Process for the preparation of benzonoprons | |
EP2345635A4 (en) | AMINO ACID DERIVATIVE | |
GB0713189D0 (en) | Amino acid derivatives | |
EP2345733A4 (en) | PROCESS FOR PREPARING N-PROTECTED AMINO ACID | |
GB0715712D0 (en) | Amino acid derivatives | |
EP2489655A4 (en) | PROCESS FOR PREPARING DIETHYLENE-TRIAMIN-PENTA-ACETIC DERIVATIVES AND DIETHYLENE-TRIAMIN-PENTA-ACETIC ACID DERIVATIVES | |
IL211382A0 (en) | Process for the preparation of ethanedinitrile | |
EP2256210A4 (en) | WICKEROL AND MANUFACTURING METHOD THEREFOR | |
GB0906872D0 (en) | Amino acid derivatives | |
PL389321A1 (pl) | Chiralny N-Cbz blokowany aminokwas dimetylocyklopropanu i sposób jego wytwarzania | |
HUP0900305A2 (en) | Peptide derivatives, process for their preparation and their therapeutical use |